vitamin-d-2 and Glomerulonephritis

vitamin-d-2 has been researched along with Glomerulonephritis* in 8 studies

Reviews

1 review(s) available for vitamin-d-2 and Glomerulonephritis

ArticleYear
Haemodialysis and tertiary hyperparathyrodism: renal homotransplantation and tubular dysfunction.
    Australasian annals of medicine, 1969, Volume: 18, Issue:2

    Topics: Acidosis, Renal Tubular; Adenoma; Adult; Alkaline Phosphatase; Anuria; Bicarbonates; Bone Diseases; Calcium; Ergocalciferols; Female; Glomerulonephritis; Glycosuria; Humans; Hypercalcemia; Hyperparathyroidism; Hypertension, Renal; Kidney Failure, Chronic; Kidney Transplantation; Parathyroid Glands; Parathyroid Neoplasms; Phosphates; Renal Dialysis; Sodium; Transplantation, Homologous

1969

Trials

2 trial(s) available for vitamin-d-2 and Glomerulonephritis

ArticleYear
The role of paricalcitol on proteinuria.
    Journal of renal care, 2011, Volume: 37, Issue:2

    Paricalcitol is a synthetic vitamin D analogue acting on vitamin D receptor (VDR). The result is inhibition of PTH synthesis and secretion. Paricalcitol appears also to block the renin-angiotensin-aldosterone system. We evaluated the role of paricalcitol in the management of proteinuria of various aetiology. A total of 19 patients participated. Most had diabetic nephropathy; however patients with other types of glomerulopathy leading to proteinuria were also included. Paricalcitol 1-2 μg daily, according to response, was administered for three months. Serum Ca, PO4, Ca × PO4, PTH, creatinine clearance and albumin, as well as 24 hour urine protein were measured before and after treatment. Five out of 19 patients did not respond to the treatment. The remaining 14 patients had an average 32.9% reduction of proteinuria. The drug was well tolerated. Paricalcitol appears to have a role in the treatment of proteinuria. However, our study raises a question regarding why some patients do not respond to paricalcitol. Patients with proteinuria due to diabetic nephropathy seem to respond better than patients with glomerulopathy.

    Topics: Aged; Aged, 80 and over; Diabetic Nephropathies; Ergocalciferols; Female; Glomerulonephritis; Humans; Male; Middle Aged; Proteinuria; Vitamins

2011
[Use of vitamin D 2 and its metabolites in chronic glomerulonephritis in children].
    Pediatriia, 1989, Issue:5

    Comparative assessment of the action of vitamin D2 in high doses, of oxydevit and rocaltrol applied in renal osteopathies has demonstrated that they are equally effective in elevating the calcium concentration in blood serum occurring at the expense of its increased absorption by the intestine. At the same time certain differences have been discovered in the action of these agents on endocrine regulation. The data obtained provide evidence in favour of the use of vitamin D2 in high doses or of its metabolites not only in renal osteopathies at the stage of chronic renal failure but also in the management of the disorders of phosphorus-calcium metabolism in patients with the nephrotic syndrome in the functional-compensation stage after continuous use of corticosteroids, heparin and diuretics.

    Topics: Adolescent; Calcitriol; Calcium; Child; Child, Preschool; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Clinical Trials as Topic; Ergocalciferols; Glomerulonephritis; Humans; Hydroxycholecalciferols; Phosphorus

1989

Other Studies

5 other study(ies) available for vitamin-d-2 and Glomerulonephritis

ArticleYear
Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats.
    American journal of physiology. Renal physiology, 2012, Jan-01, Volume: 302, Issue:1

    Angiotensin-converting enzyme (ACE) inhibitors ameliorate the progression of renal disease. In combination with vitamin D receptor activators, they provide additional benefits. In the present study, uremic (U) rats were treated as follows: U+vehicle (UC), U+enalapril (UE; 25 mg/l in drinking water), U+paricalcitol (UP; 0.8 μg/kg ip, 3 × wk), or U+enalapril+paricalcitol (UEP). Despite hypertension in UP rats, proteinuria decreased by 32% vs. UC rats. Enalapril alone, or in combination with paricalcitol, further decreased proteinuria (≈70%). Glomerulosclerosis and interstitial infiltration increased in UC rats. Paricalcitol and enalapril inhibited this. The increase in cardiac atrial natriuretic peptide (ANP) seen in UC rats was significantly decreased by paricalcitol. Enalapril produced a more dramatic reduction in ANP. Renal oxidative stress plays a critical role in inflammation and progression of sclerosis. The marked increase in p22(phox), a subunit of NADPH oxidase, and decrease in endothelial nitric oxide synthase were inhibited in all treated groups. Cotreatment with both compounds inhibited the uremia-induced increase in proinflammatory inducible nitric oxide synthase (iNOS) and glutathione peroxidase activity better than either compound alone. Glutathione reductase was also increased in UE and UP rats vs. UC. Kidney 4-hydroxynonenal was significantly increased in the UC group compared with the normal group. Combined treatment with both compounds significantly blunted this increase, P < 0.05, while either compound alone had no effect. Additionally, the expression of Mn-SOD was increased and CuZn-SOD decreased by uremia. This was ameliorated in all treatment groups. Cotreatment with enalapril and paricalcitol had an additive effect in increasing CuZn-SOD expression. In conclusion, like enalapril, paricalcitol alone can improve proteinuria, glomerulosclerosis, and interstitial infiltration and reduce renal oxidative stress. The effects of paricalcitol may be amplified when an ACE inhibitor is added since cotreatment with both compounds seems to have an additive effect on ameliorating uremia-induced changes in iNOS and CuZn-SOD expression, peroxidase activity, and renal histomorphometry.

    Topics: Aldehydes; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Enalapril; Ergocalciferols; Female; Glomerulonephritis; Kidney; NADPH Oxidases; Nitric Oxide Synthase Type II; Oxidative Stress; Proteinuria; Rats; Receptors, Calcitriol; Superoxide Dismutase; Uremia

2012
[Vitamin D metabolism in chronic glomerulonephritis (author's transl)].
    Nihon Jinzo Gakkai shi, 1981, Volume: 23, Issue:9

    Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Calcium; Chronic Disease; Ergocalciferols; Female; Glomerulonephritis; Humans; Male; Middle Aged; Phosphates; Vitamin D

1981
Plasma levels of vitamin D metabolites in renal diseases.
    Contributions to nephrology, 1980, Volume: 22

    Plasma levels of 25-OH-D, 1,25-(OH)2-D and 24,25-(OH)2-D in acute renal failure, chronic glomerulonephritis and chronic renal failure were determined by competitive protein binding assay and evaluated for the correlation with the degree of renal impairment and the influence of dialysis, renal transplantation and the administration of vitamin D and 1-alpha-OH-D3. In this study it is revealed that 25-OH-D deficiency could be normalized by the administration of vitamin D2. Plasma levels of 1,25-(OH)2-D are decreased in proportion to the degree of renal impairment and it is clearly depressed in patients, with a Ccr of 30 ml/min or less. Although biosynthesis of 24,25-(OH)2-D is not remarkably depressed, it is necessary to resolve various questions including the methods of measurement in this respect. It is also disclosed in the present study that 1-alpha-OH-D3 is faster in action than vitamin D2 when used to correct 1,25-(OH)2-D3 deficiency.

    Topics: Acute Kidney Injury; Creatinine; Dihydroxycholecalciferols; Ergocalciferols; Glomerulonephritis; Humans; Hydroxycholecalciferols; Kidney Failure, Chronic; Kidney Transplantation; Kinetics; Transplantation, Homologous

1980
Uremic polyneuropathic motor paralysis and immobilization hypercalcemia.
    Scandinavian journal of urology and nephrology, 1973, Volume: 7, Issue:1

    Topics: Adult; Bone and Bones; Calcium; Calcium Metabolism Disorders; Chronic Disease; Decalcification, Pathologic; Ergocalciferols; Female; Glomerulonephritis; Humans; Hypercalcemia; Male; Middle Aged; Osteoporosis; Paralysis; Phosphates; Polycystic Kidney Diseases; Pyelonephritis; Radiography; Renal Dialysis; Uremia

1973
Arrest of hyperparathyroid bone disease with dihydrotachysterol in patients undergoing chronic hemodialysis.
    Annals of internal medicine, 1970, Volume: 73, Issue:2

    Topics: Alkaline Phosphatase; Biopsy; Bone Resorption; Calcium; Calcium Isotopes; Chronic Disease; Dihydrotachysterol; Ergocalciferols; Glomerulonephritis; Humans; Hyperparathyroidism, Secondary; Intestinal Absorption; Nephritis; Osteitis Fibrosa Cystica; Renal Dialysis

1970
chemdatabank.com